Chronic migraine plus medication overuse headache: Two entities or not?

Journal of Headache and Pain

Volumn 12, Issue 6, 2011, Pages 593-601

  Negro, Andrea ^a,b   Martelletti, Paolo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic migraine; Detoxification; Medication overuse headache; OnabotulinumtoxinA; Refractory chronic migraine; Rehabilitation

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN A; PREDNISOLONE; TOPIRAMATE;

COMORBIDITY; DISEASE ASSOCIATION; DRUG DETOXIFICATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; TRANSFORMED MIGRAINE;

ANALGESICS; DIAGNOSIS, DIFFERENTIAL; HEADACHE DISORDERS; HEADACHE DISORDERS, SECONDARY; HUMANS; MIGRAINE WITHOUT AURA; WITHHOLDING TREATMENT;

EID: 84855659048     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-011-0388-3     Document Type: Review

References (92)

1. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742-746
2. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ, International Headache Society (2005) The international classification of headache disorders, 2nd edn (ICHD-II)-revision of criteria for 8.2 Medication- overuse headache. Cephalalgia 25:460-465
3. Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication overuse headache. Lancet Neurol 9:391-401
4. Mehlsteibl D, Schankin C, Hering P, Sostak P, Straube A (2011) Anxiety disorders in headache patients in a specialised clinic: Prevalence and symptoms in comparison to patients in a general neurological clinic. J Headache Pain 12:323-329
5. Stovner LJ, Andree C (2010) Prevalence of headache in Europe: A review of the Eurolight project. J Headache Pain 11:289-299
6. Lipton RB (2009) Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology 72:S3-S7
7. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428-432
8. Allena M, Katsarava Z, Nappi G, the COMOESTAS Consortium (2009) From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain 10:71-76
9. Bigal ME, Lipton RB (2008) Excessive acute migraine medication use and migraine progression. Neurology 71:1821-1828
10. Wiendels NJ, Knuistingh Neven A, Rosendaal FR, Spinhoven P, Zitman FG, Assendelft WJ, Ferrari MD (2006) Chronic frequent headache in the general population: Prevalence and associated factors. Cephalalgia 26:1434-1442
11. Aaseth K, Grande RB, Kvaerner KJ, Gulbrandsen P, Lundqvist C, Russell MB (2008) Prevalence of secondary chronic headaches in a population-based sample of 30-44-year-old persons. The Akershus study of chronic headache. Cephalalgia 28:705-713 (Pubitemid 351799748)
12. Wang Y, Zhou J, Fan X, Li X, Ran L, Tan G, Chen L, Wang K, Liu B (2011) Classification and clinical features of headache patients: An outpatient clinic study from China. J Headache Pain 12:561-567
13. Hershey AD (2003) Chronic daily headache in children. Expert Opin Pharmacother 4:485-491
14. Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22:269-276
15. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, Diener HC, Limmroth V (2004) Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62:788-790 (Pubitemid 38298959)
16. Gaul C, Visscher CM, Bhola R, Sorbi MJ, Galli F, Rasmussen AV, Jensen R (2011) Team players against headache: Multidisciplinary treatment of primary headaches and medication overuse headache. J Headache Pain 12:511-519
17. Scher AI, Midgette LA, Lipton RB (2008) Risk factors for headache chronification. Headache 48:16-25
18. Le H, Tfelt-Hansen P, Skytthe A, Kyvik KO, Olesen J (2011) Association between migraine, lifestyle and socioeconomic factors: A population-based cross-sectional study. J Headache Pain 12:157-172
19. Di Lorenzo C, Di Lorenzo G, Sances G, Ghiotto N, Guaschino E, Grieco GS, Santorelli FM, Casali C, Troisi A, Siracusano A, Pierelli F (2009) Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism. J Headache Pain 10:349-355
20. Bigal ME, Lipton RB (2008) Putative mechanisms of the relationship between obesity and migraine progression. Curr Pain Headache Rep 12:207-212
21. Rossi P, Jensen R, Nappi G, Allena M, the COMOESTAS Consortium (2009) A narrative review on the management of medication overuse headache: The steep road from experience to evidence. J Headache Pain 10:407-417
22. López-Mesonero L, Márquez S, Parra P, Gámez-Leyva G, Muñoz P, Pascual J (2009) Smoking as a precipitating factor for migraine: A survey in medical students. J Headache Pain 10:101-103
23. Hagen K, Thoresen K, Stovner LJ (2009) High dietary caffeine consumption is associated with a modest increase in headache prevalence: Results from the Head-HUNT Study. J Headache Pain 10:153-159
24. Ødegård SS, Engstrøm M, Sand T, Stovner LJ, Zwart JA, Hagen K (2010) Associations between sleep disturbance and primary headaches: The third Nord-Trøndelag Health Study. J Headache Pain 11:197-206
25. Rains JC, Poceta S (2006) Headache and sleep disorders: Review and clinical implications for headache management. Headache 46:1344-1363 (Pubitemid 44556427)
26. Yokoyama M, Yokoyama T, Funazu K, Yamashita T, Kondo S, Hosoai H, Yokoyama A, Nakamura H (2009) Associations between headache and stress, alcohol drinking, exercise, sleep, and comorbid health conditions in a Japanese population. J Headache Pain 10:177-185
27. Leistad RB, Nilsen KB, Stovner LJ, Westgaard RH, Rø M, Sand T (2008) Similarities in stress physiology among patients with chronic pain and headache disorders: Evidence for a common pathophysiological mechanism? J Headache Pain 9:165-175
28. Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A (2011) Migraine and psychiatric comorbidity: A review of clinical findings. J Headache Pain 12:115-125
29. Mercante JP, Peres MF, Bernik MA (2011) Primary headaches in patients with generalized anxiety disorder. J Headache Pain 12:331-338
30. Winter AC, Hoffmann W, Meisinger C, Evers S, Vennemann M, Pfaffenrath V, Fendrich K, Baumeister SE, Kurth T, Berger K (2011) Association between lifestyle factors and headache. J Headache Pain 12:147-155
31. Pascual J (2011) Prevalence of primary headaches: It is not the behavior, but still we have to pay attention to it. J Headache Pain 12:139-140
32. Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zanigni S, Nicodemo M, Cortelli P, Montagna P (2009) Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache 48:412-418
33. Prakash S, Mehta NC, Dabhi AS, Lakhani O, Khilari M, Shah ND (2010) The prevalence of headache may be related with latitude: A possible role of vitamin D insufficiency? J Headache Pain 11:301-307
34. Katić BJ, Golden W, Cady RK, Hu XH (2009) GERD prevalence in migraine patients and the implication for acute migraine treatment. J Headache Pain 10:35-43
35. Rainero I, Rubino E, Gallone S, Fenoglio P, Picci LR, Giobbe L, Ostacoli L, Pinessi L (2011) Evidence for an association between migraine and the hypocretin receptor 1 gene. J Headache Pain 12:193-199
36. Bigal ME, Lipton RB (2009) Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 13:301-307
37. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME (2006) Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 46:766-772
38. Martelletti P (2011) Dispute settlement understanding on the use of BOTOX® in chronic migraine. J Headache Pain 12:1-2
39. Negro A, D'Alonzo L, Martelletti P (2010) Chronic migraine: Comorbidities, risk factors, and rehabilitation. Intern Emerg Med 5:S13-S19
40. Obermann M, Katsarava Z (2007) Management of medication overuse headache. Expert Rev Neurother 7:1145-1155
41. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V (2001) Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 57:1694-1698 (Pubitemid 33055491)
42. Pageler L, Katsarava Z, Diener HC, Limmroth V (2008) Prednisone versus placebo in withdrawal therapy following medication overuse headache. Cephalalgia 28:152-156
43. Pamelaire K, Crevits L, Goadsby PJ, Haube H (2006) Practical management of medication overuse headache. Acta Neurol Belg 106:43-51 (Pubitemid 44044033)
44. Krymchantowski AV, Moreira PF (2003) Outpatient detoxification in chronic migraine: Comparison of strategies. Cephalalgia 23:982-993 (Pubitemid 37521952)
45. Bøe MG, Mygland A, Salvesen R (2007) Prednisolone does not reduce withdrawal headache. Neurology 69:26-31
46. Rossi P, Faroni JV, Nappi G (2011) Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol 18:396-401
47. Hagen K, Jensen R, Bøe MG, Stovner LJ (2010) Medication overuse headache: A critical review of end points in recent followup studies. J Headache Pain 11:373-377
48. Diener HC, Limmroth V (2004) Medication-overuse headache: A worldwide problem. Lancet Neurol 3:475-483 (Pubitemid 38903098)
49. Hering R, Steiner TJ (1991) Abrupt outpatient withdrawal of medication in analgesic abusers migraineurs. Lancet 337: 1142-1443
50. Suhr B, Evers S, Bauer B, Gralow I, Grotemeyer KH, Husstedt IW (1999) Drug-induced headache: Long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia 19:44-49 (Pubitemid 29136851)
51. Grazzi L, Andrasik F, Usai S, Bussone G (2008) In-patient vs. day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: Results at one-year follow-up. Neurol Sci 29:161-163
52. Trucco M, Meineri P, Ruiz L, Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee (Neurological Hospital Interregional Group for the Study of Headaches) (2010) Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain 6:334-337
53. Valguarnera F, Tanganelli P (2010) The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci 31:S175-S177
54. Steiner TJ, MacGregor EA, Davies PTG for the British Association for the study of Headache (2007) Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache, 3rd edn. http://216.25.100.131/upload/NS.BASH/BASH- guidelines. 2007.pdf. Accessed in April 2008
55. Rapoport AM (2008) Medication overuse headache: Awareness, detection and treatment. CNS Drugs 22:995-1004
56. Andrasik F, Grazzi L, Usai S, D'Amico D, Kass S, Bussone G (2007) Disability in chronic migraine with medication overuse: Treatment effect at 3 years. Headache 47:1277-1281 (Pubitemid 47561505)
57. Zidvert-Trajkovic J, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, Sternic N (2007) Medication overuse headache: Clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 27:1219-1225 (Pubitemid 47631900)
58. Baumgartner C, Wessely P, Bingö l C, Maly J, Holzner F (1989) Long-term prognosis of analgesic withdrawal in patients with drug-induced headache. Headache 29:510-514 (Pubitemid 20318931)
59. Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V (2005) Medication overuse headache: Rates and predictors for relapse in a 4-year prospective study. Cephalalgia 25:12-15 (Pubitemid 40143787)
60. Hagen K, Albretsen C, Vilming ST, Salvesen R, Grønning M, Helde G, Gravdahl G, Zwart JA, Stovner LJ (2011) A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study. J Headache Pain 12:315-322
61. Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC (2001) Drug-induced headache: Long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 45:229-235 (Pubitemid 32521040)
62. Rossi P, Faroni JV, Nappi G (2008) Medication overuse headache: Predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 28: 1196-1200
63. Boe MG, Salvesen R, Mygland A (2009) Chronic daily headache with medication overuse: Predictors of outcome 1 year after withdrawal therapy. Eur J Neurol 16:705-712
64. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343-349 (Pubitemid 46184209)
65. Antonaci F, Dumitrache C, De Cillis I, Allena M (2010) A review of current European guidelines for migraine. J Headache Pain 11:13-19
66. D'Amico D, Solari A, Usai S, Santoro P, Bernardoni P, Frediani F, De Marco R, Massetto N, Bussone G, Progetto Cefalee Lombardia Group (2006) Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia 26:691-696
67. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT-MIG-201(TOP-CHROME) Study Group (2007) Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 27:814-823 (Pubitemid 46961730)
68. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J, Group TopiramateChronicMigraineStudy (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo- controlled trial. Headache 47:170-180
69. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group (2004) Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 61:490-495 (Pubitemid 38923736)
70. Ruiz L, Ferrandi D (2009) Topiramate in migraine progression. J Headache Pain 10:419-422
71. Göbel H (2004) Botulinum toxin in migraine prophylaxis. J Neurol 251:8-11 (Pubitemid 38299760)
72. Mathew NT, Jaffri SFA (2009) A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study. Headache 49:1466-1478
73. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU (2011) A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 51:21-32
74. Láinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S (2007) Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 14:900-906 (Pubitemid 47106778)
75. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache 45:293-307 (Pubitemid 40530193)
76. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC (2005) Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, doubleblind, placebocontrolled trial. Mayo Clin Proc 80:1126-1137 (Pubitemid 41233350)
77. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized placebo-controlled phases of the PREEMPT clinical program. Headache 50:921-936
78. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793-803
79. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for threatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804-814
80. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ (2010) Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406-1418
81. Olesen J, Tfelt-Hansen P (2010) Licence for Botox in so-called chronic migraine. Lancet 376:1825-1826
82. Russell MB (2011) Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 12:135-136
83. Aurora S, Diener HC, Dodick D, PREEMPT Chronic Migraine Study Group (2011) Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 12:137-138
84. Gerwin R (2011) Treatment of chronic migraine headache with onabotulinumtoxinA. Curr Pain Headache Rep. doi:10.1007/ s11916-011-0202-6
85. Cady R, Schreiber C (2008) Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48:900-913 (Pubitemid 351795552)
86. Mathew NT, Kailasam J, Meadors L (2008) Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 48:194-200 (Pubitemid 351178284)
87. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: A multicenter, doubleblind, randomized, placebo-controlled, parallel group study. J Headache Pain 12:427-433
88. Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW (2005) Duration of migraine is a predictor for response to botulinum toxin type A. Headache 45:308-314 (Pubitemid 40530194)
89. Oterino A, Ramón C, Pascual J (2011) Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: Focus on severe attacks. J Headache Pain 12:235-238
90. Christie SN, Giammarco R, Gawel M, Mackie G, Gladstone J, Becker WJ (2010) Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 37:588-594
91. Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P (2010) Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 11:151-156
92. Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 11:431-435